Literature DB >> 11451677

Kinetic study of two novel enantiomeric tricyclic beta-lactams which efficiently inactivate class C beta-lactamases.

M Vilar1, M Galleni, T Solmajer, B Turk, J M Frère, A Matagne.   

Abstract

A detailed kinetic study of the interaction between two ethylidene derivatives of tricyclic carbapenems, Lek 156 and Lek 157, and representative beta-lactamases and D-alanyl-D-alanine peptidases (DD-peptidases) is presented. Both compounds are very efficient inactivators of the Enterobacter cloacae 908R beta-lactamase, which is usually resistant to inhibition. Preliminary experiments indicate that various extended-spectrum class C beta-lactamases (ACT-1, CMY-1, and MIR-1) are also inactivated. With the E. cloacae 908R enzyme, complete inactivation occurs with a second-order rate constant, k(2)/K', of 2 x 10(4) to 4 x 10(4) M(-1) s(-1), and reactivation is very slow, with a half-life of >1 h. Accordingly, Lek 157 significantly decreases the MIC of ampicillin for E. cloacae P99, a constitutive class C beta-lactamase overproducer. With the other serine beta-lactamases tested, the covalent adducts exhibit a wide range of stabilities, with half-lives ranging from long (>4 h with the TEM-1 class A enzyme), to medium (10 to 20 min with the OXA-10 class D enzyme), to short (0.2 to 0.4 s with the NmcA class A beta-lactamase). By contrast, both carbapenems behave as good substrates of the Bacillus cereus metallo-beta-lactamase (class B). The Streptomyces sp. strain R61 and K15 extracellular DD-peptidases exhibit low levels of sensitivity to both compounds.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11451677      PMCID: PMC90634          DOI: 10.1128/AAC.45.8.2215-2223.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

Review 1.  beta-Lactamases of increasing clinical importance.

Authors:  K Bush
Journal:  Curr Pharm Des       Date:  1999-11       Impact factor: 3.116

2.  Interactions between active-site serine beta-lactamases and so-called beta-lactamase-stable antibiotics. Kinetic and molecular modelling studies.

Authors:  A Matagne; J Lamotte-Brasseur; J M Frère
Journal:  Eur J Biochem       Date:  1993-10-01

3.  Serine-type D-Ala-D-Ala peptidases and penicillin-binding proteins.

Authors:  B Granier; M Jamin; M Adam; M Galleni; B Lakaye; W Zorzi; J Grandchamps; J M Wilkin; C Fraipont; B Joris
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

4.  Interactions between active-site-serine beta-lactamases and compounds bearing a methoxy side chain on the alpha-face of the beta-lactam ring: kinetic and molecular modelling studies.

Authors:  A Matagne; J Lamotte-Brasseur; G Dive; J R Knox; J M Frère
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

Review 5.  Inactivation of antibiotics and the dissemination of resistance genes.

Authors:  J Davies
Journal:  Science       Date:  1994-04-15       Impact factor: 47.728

6.  Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors.

Authors:  X Y Zhou; F Bordon; D Sirot; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

7.  TEM beta-lactamase mutants hydrolysing third-generation cephalosporins. A kinetic and molecular modelling analysis.

Authors:  X Raquet; J Lamotte-Brasseur; E Fonzé; S Goussard; P Courvalin; J M Frère
Journal:  J Mol Biol       Date:  1994-12-16       Impact factor: 5.469

8.  The mechanism of action of DD-peptidases: the role of tyrosine-159 in the Streptomyces R61 DD-peptidase.

Authors:  J M Wilkin; M Jamin; C Damblon; G H Zhao; B Joris; C Duez; J M Frère
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

9.  Kinetic and physical studies of beta-lactamase inhibition by a novel penem, BRL 42715.

Authors:  T H Farmer; J W Page; D J Payne; D J Knowles
Journal:  Biochem J       Date:  1994-11-01       Impact factor: 3.857

10.  Interactions between active-site-serine beta-lactamases and mechanism-based inactivators: a kinetic study and an overview.

Authors:  A Matagne; M F Ghuysen; J M Frère
Journal:  Biochem J       Date:  1993-11-01       Impact factor: 3.857

View more
  6 in total

1.  Kinetics of the Interaction between BAL29880 and LK157 and the Class C β-Lactamase CHE-1.

Authors:  Adriana Fernea; Moreno Galleni; Jean-Marie Frère
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

2.  In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor.

Authors:  Susanne Paukner; Lars Hesse; Andrej Prezelj; Tomaz Solmajer; Uros Urleb
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 3.  Carbapenems: past, present, and future.

Authors:  Krisztina M Papp-Wallace; Andrea Endimiani; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

4.  Design, synthesis, crystal structures, and antimicrobial activity of sulfonamide boronic acids as β-lactamase inhibitors.

Authors:  Oliv Eidam; Chiara Romagnoli; Emilia Caselli; Kerim Babaoglu; Denise Teotico Pohlhaus; Joel Karpiak; Richard Bonnet; Brian K Shoichet; Fabio Prati
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

Review 5.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

6.  Biochemical characterization of CTX-M-15 from Enterobacter cloacae and designing a novel non-β-lactam-β-lactamase inhibitor.

Authors:  Mohammad Faheem; Md Tabish Rehman; Mohd Danishuddin; Asad U Khan
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.